Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: HIV Prevention, HIV Pre-exposure Prophylaxis, Access and Linkage to Healthcare, Technology Use
Interventions: PEPPI Pharmacies; Other
Lead sponsor: EMPOWERX INC; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Del Mar, California

Conditions: PTSD
Interventions: Attention Control Training, Comparison Task; Behavioral
Lead sponsor: Creighton University; Other
Eligibility: 7 Years to 15 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Oncology
Interventions: Nudge; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium Inhalation Solution, Placebo; Drug · Other
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,007 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 9 more

Conditions: Persistent Corneal Epithelial Defect
Interventions: Cenegermin, Vehicle; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 18
States / cities: Huntington Beach, California • Laguna Hills, California • Loma Linda, California + 14 more

Conditions: Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
Interventions: Heplisav-B Injectable Product, 2-dose regimen, Heplisav-B Injectable Product, 3-dose regimen; Biological
Lead sponsor: Mercy Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Kidney Disease (Stages 4 and 5)
Interventions: Kidney RISE; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Smoking
Interventions: THS 2.2 Menthol (mTHS 2.2), Menthol Conventional Cigarette (mCC), Smoking Abstinence (SA); Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 22 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Asthma
Interventions: Tiotropium low dose QD, Tiotropium high dose QD, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: Columbia, Missouri • Cincinnati, Ohio • Oklahoma City, Oklahoma + 3 more

Conditions: Morbid Obesity, Pregnancy
Interventions: Misoprostol; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Facial Papulopustular Rosacea
Interventions: FMX103 minocycline foam 1.5%, Vehicle foam; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 54
States / cities: Tucson, Arizona • Fremont, California • Los Angeles, California + 46 more

Conditions: Clostridioides Difficile Infection
Interventions: Ridinilazole, Vancomycin; Drug
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • Orange, California • Miami, Florida + 11 more

Conditions: Bipolar I Disorder, Alcohol Dependence
Interventions: Quetiapine fumarate, lithium, divalproex; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 38
States / cities: Cerritos, California • San Diego, California • New Haven, Connecticut + 35 more

Conditions: Gestational Diabetes
Interventions: Insulin, Metformin; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Attention-deficit/Hyperactivity Disorder
Interventions: Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 81
States / cities: Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 68 more

Conditions: Smoking Cessation, Pregnancy
Interventions: Bupropion SR, placebo, smoking cessation counseling; Drug · Behavioral
Lead sponsor: Watching Over Mothers & Babies Foundation; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Traumatic Brain Injury, Dysautonomia
Interventions: Esmolol, Propranolol; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infections, Meningococcal
Interventions: Bexsero, Saline Placebo, Havrix, MenABCWY; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 1,063 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 13
States / cities: Jonesboro, Arkansas • Hialeah, Florida • Melbourne, Florida + 10 more

Conditions: Non-Specific Chronic Lower Back Pain
Interventions: NexWave, Sham; Device
Lead sponsor: Zynex Medical, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 8
States / cities: Greenwood Village, Colorado • Saint Augustine, Florida • Atlanta, Georgia + 5 more

Conditions: Healthy
Interventions: Controlled-Release Oxycodone Hydrochloride 40 mg, OxyContin® 40 mg tablet; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Liver Transplantation
Interventions: Normothermic Machine Perfusion (NMP), Standard of Care (Ice); Device · Other
Lead sponsor: OrganOx Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more

Conditions: Reduction in Bacterial Counts Through the Use of Mouthwash
Interventions: Mouthwash; Other
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP); Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 6
States / cities: Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more

Conditions: Dry Eye
Interventions: tanfanercept, Vehicle; Drug
Lead sponsor: HanAll BioPharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Delray Beach, Florida

Search by objective public record fields.

PEP/PrEP Via Pharmacist-Prescribing Implementation (PEPPI)

Attention Control Training for PTSD in Children

Machine-Generated Mortality Estimates and Nudges to Promote Advance Care Planning Discussion Among Cancer Patients

Tiotropium / Respimat One-Year Study

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Kidney RISE: Randomized Integrated Supportive CarE Trial

Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

Induction of Labor in Morbidly Obese Patients

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder

Comparison of Insulin Alone to Insulin With Metformin to Treat Gestational Diabetes Mellitus

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Bupropion for Smoking Cessation in Pregnancy

Controlling Hyperadrenergic Activity in Neurologic Injury

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Randomized Blinded Evaluation of the Effects of TENS and IFC Compared to a Sham Device and SOC in Patients With Non-Specific CLBP

Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets

WP01 - Normothermic Liver Preservation

Dental Implants and Mouth Rinse

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease